IXICO plc New contract in Huntington's disease (0234S)

TIDMIXI

RNS Number : 0234S

IXICO plc

28 September 2017

28(th) September 2017

IXICO plc

("IXICO" or the "Company")

New contract in Huntington's disease with US-based pharmaceutical company

IXICO plc (AIM: IXI), the digital technologies company serving neuroscience, today announces that it has signed a new contract with a customer for its technology enabled imaging services. The contract value is US$690k over a two and a half year term.

This new contract is for a Phase II clinical trial evaluating the safety and tolerability of a novel treatment for patients with Huntington's disease. As part of the study, IXICO will use its TrialTracker(TM) digital platform and scientific services to provide a battery of advanced MRI imaging techniques and clinical trial endpoints.

Giulio Cerroni, CEO of IXICO, commented

"We are delighted to announce this contract, building on our successful track record as the partner of choice in Huntington's disease clinical studies. This new contract further demonstrates the value our customers see in IXICO's deep neurological disease expertise combined with our proprietary digital technologies in providing compliant data standardisation, collection and analysis."

For further information please contact:

 
 IXICO plc 
  Giulio Cerroni, Chief Executive            Tel: +44 20 
  Officer                                    3763 7499 
  Susan Lowther, Chief Financial Officer 
 
 Shore Capital (Nomad and Broker)          Tel: +44 20 
  Bidhi Bhoma / Edward Mansfield /James     7408 4090 
  Wolfe 
 
 FTI Consulting Limited (Investor          Tel: +44 20 
  Relations)                                3727 1000 
  Simon Conway/Mo Noonan

About IXICO

IXICO is the digital technologies company serving neuroscience. Our mission is to transform the pursuit of improving brain health through the application of digital technologies to neuroscience. IXICO's specialist data analytics services are used by the global pharmaceutical industry to select participants for clinical trials, assess the safety and efficacy of new drugs in development and in post marketing surveillance. Our neurological disease focus includes Alzheimer's disease, Huntington's disease, Multiple Sclerosis, Parkinson's disease and our integrated digital platform encompasses the entire drug development lifecycle. It is a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable sponsors to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new companion digital health products targeted at improving patient outcomes.

More information is available on www.IXICO.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

CNTQDLFLDKFZBBX

(END) Dow Jones Newswires

September 28, 2017 02:00 ET (06:00 GMT)

Ixico (LSE:IXI)
Historical Stock Chart
From Mar 2024 to Apr 2024